US 12,599,668 B2 · Antibodies

Abstract

The invention relates to antibodies and antigen-binding fragments thereof that recognize coronavirus spike proteins(CoV-S), such as the spike protein of Middle East respiratory syndrome coronavirusspike protein(MERS-S). In some embodiments, the antibodiesbind to CoV-S with high affinity, inhibit CoV infection of human cells, inhibit CoV sialic acid-binding activity and/or bind to multiple types of CoV-S. In some embodiments, the antibodies provide a means of preventing, treating or ameliorating CoV infection.

An antibody that binds to Middle East Respiratory Syndrome coronavirus (MERS-CoV) spike protein (MERS-S), wherein the antibody comprises a heavy chain that comprises a heavy chain variable region (VH) and a light chain that comprises a light chain variable region (VL):

wherein:
(a) the VH comprises a heavy chain complementarity determining region (CDR) 1 with a sequence of SEQ ID NO:
83, a heavy chain CDR2 with a sequence of SEQ ID NO:
84, and a heavy chain CDR3 with a sequence of SEQ ID NO:
85;
and the VL comprises a light chain CDR1 with a sequence of SEQ ID NO:
86;
a light chain CDR2 with a sequence of SEQ ID NO:
87, and a light chain CDR3 with a sequence of SEQ ID NO:
88,
(b) the VH comprises a heavy chain CDR1 with a sequence of SEQ ID NO:
89, a heavy chain CDR2 with a sequence of SEQ ID NO:
90, and a heavy chain CDR3 with a sequence of SEQ ID NO:
91;
and the VL comprises a light chain CDR1 with a sequence of SEQ ID NO:
92, a light chain CDR2 with a sequence of SEQ ID NO:
93, and a light chain CDR3 with a sequence of SEQ ID NO:
94,
(c) the VH comprises a heavy chain CDR1 with a sequence of SEQ ID NO:
139, a heavy chain CDR2 with a sequence of SEQ ID NO:
140, and a heavy chain CDR3 with a sequence of SEQ ID NO:
141;
and the VL comprises a light chain CDR1 with a sequence of SEQ ID NO:
142, a light chain CDR2 with a sequence of SEQ ID NO:
143, and a light chain CDR3 with a sequence of SEQ ID NO:
144,
(d) the VH comprises a heavy chain CDR1 with a sequence of SEQ ID NO:
133, a heavy chain CDR2 with a sequence of SEQ ID NO:
134, and a heavy chain CDR3 with a sequence of SEQ ID NO:
135;
and the VL comprises a light chain CDR1 with a sequence of SEQ ID NO:
136, a light chain CDR2 with a sequence of SEQ ID NO:
137, and a light chain CDR3 with a sequence of SEQ ID NO:
138,
(e) the VH comprises a heavy chain CDR1 with a sequence of SEQ ID NO:
127, a heavy chain CDR2 with a sequence of SEQ ID NO:
128, and a heavy chain CDR3 with a sequence of SEQ ID NO:
129;
and the VL comprises a light chain CDR1 with a sequence of SEQ ID NO:
130, a light chain CDR2 with a sequence of SEQ ID NO:
131, and a light chain CDR3 with a sequence of SEQ ID NO:
132,
(f) the VH comprises a heavy chain CDR1 with a sequence of SEQ ID NO:
95, a heavy chain CDR2 with a sequence of SEQ ID NO:
96, and a heavy chain CDR3 with a sequence of SEQ ID NO:
97;
and the VL comprises a light chain CDR1 with a sequence of SEQ ID NO:
98, a light chain CDR2 with a sequence of SEQ ID NO:
99, and a light chain CDR3 with a sequence of SEQ ID NO:
100,
(g) the VH comprises a heavy chain CDR1 with a sequence of SEQ ID NO:
101, a heavy chain CDR2 with a sequence of SEQ ID NO:
102, and a heavy chain CDR3 with a sequence of SEQ ID NO:
103;
and the VL comprises a light chain CDR1 with a sequence of SEQ ID NO:
104, a light chain CDR2 with a sequence of SEQ ID NO:
105, and a light chain CDR3 with a sequence of SEQ ID NO:
106,
(h) the VH comprises a heavy chain CDR1 with a sequence of SEQ ID NO:
109, a heavy chain CDR2 with a sequence of SEQ ID NO:
110, and a heavy chain CDR3 with a sequence of SEQ ID NO:
111;
and the VL comprises a light chain CDR1 with a sequence of SEQ ID NO:
112, a light chain CDR2 with a sequence of SEQ ID NO:
113, and a light chain CDR3 with a sequence of SEQ ID NO:
114,
(i) the VH comprises a heavy chain CDR1 with a sequence of SEQ ID NO:
145, a heavy chain CDR2 with a sequence of SEQ ID NO:
146, and a heavy chain CDR3 with a sequence of SEQ ID NO:
147;
and the VL comprises a light chain CDR1 with a sequence of SEQ ID NO:
148, a light chain CDR2 with a sequence of SEQ ID NO:
149, and a light chain CDR3 with a sequence of SEQ ID NO:
150, or
(j) the VH comprises a heavy chain CDR1 with a sequence of SEQ ID NO:
617, a heavy chain CDR2 with a sequence of SEQ ID NO:
618, and a heavy chain CDR3 with a sequence of SEQ ID NO:
619;
and the VL comprises a light chain CDR1 with a sequence of SEQ ID NO:
614, a light chain CDR2 with a sequence of SEQ ID NO:
615, and a light chain CDR3 with a sequence of SEQ ID NO:
616.

79 more elements

Antibodies

Life of this patent

Antibodies

Life of this patent

Abstract

Claims11